Cellular immunity is important for the control of CMV infection after allogeneic hematopoietic cell transplantation (Allo-HCT). However, the actual in vivo dynamics of CMV-specific cytotoxic T cell (CMV-CTL) clones are still unclear. We conducted clone monitoring of tetramer þ CMV-CTLs in HLA-A*2402-positive donor-patient pairs, using a direct single-cell analysis that enabled the simultaneous identification and quantification of CTL clones. Clone dynamics were assessed in three cases with or without CMV reactivation. In Case-1 without CMV reactivation, despite the long-term use of systemic steroid, dominant clones of Donor-1 persisted and remained dominant. The CMV-CTLs at 1 year after Allo-HCT included a high proportion of CD45RA þ CCR7 À effector and CD27
INTRODUCTION
CMV reactivation is one of the major concerns after allogeneic hematopoietic cell transplantation (Allo-HCT). 1, 2 It is important to control CMV reactivation before it progresses to diseases such as pneumonia because CMV diseases are associated with high mortality. 3, 4 In addition to recent pre-emptive therapy, immunological reconstitution against CMV is necessary for long-term suppression of CMV reactivation.
Cellular immunity by CMV-specific cytotoxic T cells (CMV-CTL) is considered to have a major role in the control of CMV reactivation after Allo-HCT. HLA-restricted CMV-CTLs are identified by tetramer methods. 5, 6 An individual CTL has a specific complementaritydetermining region 3 (CDR3) of the T-cell receptor (TCR)-b, which is a result of the recombination of somatic TCR V-(D)-J genes and junction diversity. The repertoire of TCR and clones of CMV-CTLs have thus far been identified after in vitro bulk expansion, and therefore the results obtained to date may have been affected by the potential proliferation of CMV-CTL clones and bacterialtransforming efficiency. [7] [8] [9] [10] Recently, we and others have developed a direct single-cell RT-PCR analysis that enables the simultaneous identification and quantification of CTL clones without the effects of in vitro expansion. 11, 12 To the best of our knowledge, the in vivo dynamics and monitoring of CMV-CTL clones have not been assessed in Allo-HCT. In addition, the clonotypes in HLA-A*2402-restricted CMV-CTLs have not been clarified, even though HLA-A*2402 is the most common HLA-A allele in the Japanese population (B60%).
In this study, we investigated the TCR-b repertoire and clone monitoring of HLA-A*2402-restricted CMV-pp65 341-349 (QYDP-VAALF)-specific CTLs (CMV-pp65 CTLs) in Allo-HCT and found three distinct patterns of reconstitution for CMV-pp65 CTL clones.
CD8, CD4, CD14, CD16, CD19 and CD56 mAb (BD Biosciences, Tokyo, Japan). Data were analyzed with FACSCalibur and CellQuest (BD Biosciences). HLA-A*2402-restricted CMV-pp65 CTLs were defined as CD8
þ CMV-tetramer þ T cells. The proportions of CMV-pp65 CTLs to whole CD8 þ T cells were monitored every 1-3 months. We described the sampling phases as follows: the early phase, 1-3 months after Allo-HCT; the intermediate phase, about 6-9 months and the late phase, over 1 year after Allo-HCT.
Furthermore, phenotypic analysis was performed using non-cultured samples when sufficient CMV tetramer þ T cells were detected for the first time after Allo-HCT and thereafter every 4-6 months: (Case-1) days 40, 215 and 376; (Case-2) days 58, 240 and 388; (Case-3) days 92, 264 and 416. Cells were incubated with CMV tetramer, and then stained with anti-human CD3, CD8, CD45RA and CCR7 mAbs (BD Biosciences). T cells were divided into four differentiation subsets according to their phenotypes: CD45RA Single-cell TCR-b analysis of individual HLA-A*2402-restricted CMV-pp65 CTLs and clone monitoring Clone identification by single-cell analysis was performed. The clone dynamics of each recipient was assessed using the same samples for phenotypic analysis. In Case-3, the proportions of CMV-tetramer þ T cells were extremely low, and therefore samples on days 264 and 416 were combined with those on days 290 and 451, respectively. Thereafter, individual CD3 þ CD8 þ CMV-tetramer þ T cells were directly sorted as single cells into PCR tubes or microplates using FACSAria II (BD Biosciences). A median of 120 cells was sorted (range: 73-165) for each sample. The aminoacid (AA) sequences in CDR3 of TCR-b for sorted cells at a single-cell level were directly analyzed and determined after reverse transcript (RT)-PCR for TCR-b gene amplification as described previously. 11, 12 In brief, individual CMV-pp65 tetramer þ T cells were sorted at a single-cell level into PCR tubes. After direct cell lyses, cDNAs of TCR-b were synthesized by RT, with a TCR-b constant region gene-specific primer. The synthesized cDNA of TCR-b were used for two sequential steps of semi-nested PCR using 24 kinds of TCR-b variable region (BV) gene family-specific primers and two kinds of TCR-b constant primers. After we identified the BV family of individual cells, we directly sequenced AA of V-D-J CDR3 of T cells. The average efficiency of TCR analysis was 68: 77 in Case-1, 70 in Case-2 and 58% in Case-3.
Induction of CMV-pp65 CTLs in donor cells by culture in bulk
To compare the differences in the distribution of CMV-CTL clones between cultured and non-cultured cells, we cultured donor cells with 10 mg/mL of CMV-pp65 341-349 peptide (QYDPVAALF) (Sigma Genosys, Tokyo, Japan) in RPMI 1640 (Sigma, Tokyo, Japan) containing 10% fetal bovine serum (FBS). One day after peptide stimulation, 50 IU/mL of IL-2 (Shionogi, Osaka, Japan) were added to the medium. Thereafter, the medium was replaced with fresh medium that contained the same concentration of IL-2, as determined by the medium color. After 2 weeks, the cultured cells were collected and the repertoire of TCR-b in CMV-pp65 CTLs was analyzed as described above.
Establishment of a CMV-pp65 CTL clone from a single cell To assess the cytotoxic effect of CMV-pp65 CTLs, CTL clones were established from the sample from Case-1 at 334 days after Allo-HCT. First, cells were cultured with 10 ng/mL of CMV-pp65 341-349 peptide in AIM-V (Life Technologies, Tokyo, Japan) with 10% human AB serum (Sigma). Two days after peptide stimulation, 50 IU/mL of IL-2 (Shionogi) were added. Thereafter, the medium was replaced with fresh medium that contained the same concentration of IL-2, as determined by the medium color. After 2 weeks, the cultured cells were collected and stained with CMV tetramer, anti-human CD3, CD8 and 7AAD mAbs (BD Biosciences). The CD8
þ CMVtetramer þ T cells were sorted at a single-cell level into 96-well microplates with 100 mL/well of AIM-V containing 10% human AB serum, 5 mg/mL of PHA, 200 IU/mL of IL-2, and allo-feeder cells treated by mitomycin C. After 1 week, an additional 100 mL/well of AIM-V containing 10% human AB serum and 200 IU/mL of IL-2 were suspended in each well. After 4-6 weeks, cells were collected and we determined whether or not the proliferated cells were CD8
þ CMV-tetramer þ T cells. In Cases-2 and -3, CMV-pp65 CTL clones did not proliferate sufficiently.
Cytotoxicity of CMV-CTL clones
A fluorochromasia cytotoxicity assay was performed with a TERASCAN VPC system (Minerva Tech, Tokyo, Japan) according to previous reports. [18] [19] [20] Briefly, T2-24 cells that expressed HLA-A*2402 (kindly provided by Professor Kawakami of Keio University) were pulsed with 10 mg/mL of CMV-pp65 341-349 peptide (QYDPVAALF) or 10 mg/mL of HIV env gp 160 (RYLRDQQLL) (Sigma Genosys) for 1 h. The T2-24 cells as a target were then stained with calcein AM (WAKO, Osaka, Japan) for 30 min. After being washed three times, 1 Â 10 4 T2-24 cells per well were suspended in a 96-well half area plate (Corning, Tokyo, Japan) and cultured with individual CMV-pp65 CTL clones in a dose-dependent manner. After 4 h, the release of calcein was measured and cytotoxicity was calculated.
RESULTS

Proportions and phenotypes of HLA-A*2402-restricted CMV-pp65
CTLs during the clinical courses The patient backgrounds are shown in Table 1 . Engraftment was successfully achieved in all three cases. Case-1 did not have CMV reactivation (Figure 1a ). Case-1 experienced grade 2 acute GVHD and extensive chronic GVHD at 40 and 314 days after HCT, respectively. Although both the acute and chronic GVHD required steroid treatment, clinical CMV reactivation did not occur during the follow-up. Donor-1 showed a 0.66% CMV-pp65 CTLs, which included 67% CD45RA þ CCR7 À T EF and 27% CD45RA À CCR7 À T EM cells (Figure 1b) . The CMV-pp65 CTLs in the recipient appeared at 40 days after HCT and accounted for 5.2% of CD8 þ T cells. During the first 3 months, CMV-pp65 CTLs maintained a proportion of about 5% of CD8 þ T cells. Thereafter, the proportion of CMV-pp65 CTLs decreased, but remained at about 1-2% ( Figure 1a ). The proportion of CD45RA þ CCR7 À T EF cells in CMV-pp65 CTLs remained at 60-80% after Allo-HCT (Figure 1b ).
Case-2 showed a CMV reactivation only in the early phase ( Figure 1c ). Case-2 did not experience acute GVHD, but developed 
Single-cell TCR-b analysis of CMV-CTLs in Allo-HCT H Nakasone et al limited chronic GVHD, which did not require steroid treatment. Donor-2 had 0.03% CMV-pp65 CTLs, almost all of which were CD45RA À CCR7 À T EM cells (Figure 1d ). Clinical CMV reactivation occurred 35 days after Allo-HCT and disappeared with GCV treatment. The CMV-pp65 CTLs accounted for 0.19% of CD8 þ T cells at 2 months after HCT. Thereafter, the proportion of CMVpp65 CTLs decreased and remained at about 0.02-0.08% (Figure 1c) . The CMV-pp65 CTLs after Allo-HCT included CD45RA Of the total 993 cells, 187 clones were identified: 30, 74 and 83 in Cases-1, -2 and -3, respectively. Table 2 shows the features of clones that appeared in three or more cells during the follow-up. Within each case, specific AA sequences of CDR3 were found: DPG in Case-1, GQG and PRD in Case-2, and QVS in Case-3. Although no common AA motif of CDR3 was found among the three cases, GGGG was seen in the dominant clones in both Cases-1 and -3 ( Table 2) . 100%  50%  0%  100%  50%  0%  100%  50%  0%  100%  50%  0%  100%  50%   100%  50%  40%  20%  100%  50%  40%  20%  0%  40%  20%   0%  0%  0%  0%  100%  50%  40%  20%  40%  20%  40%  20% 0% 40% 20% (Figures 3a-c) . In Case-1, who did not show CMV reactivation during the follow-up, the dominant CMV-pp65 CTL clones in the donor were well preserved in the recipient after Allo-HCT (Figure 3a) . Especially, clone N-1 with CAISDPGHRFGEAFF of CDR3-AA always exceeded 50% in Case-1. Few novel clones (o10%) appeared during the follow-up.
In Case-2, who developed CMV reactivation only within the early phase after HCT, the dominant CMV-CTL clones in the donor were preserved in the early phase after Allo-HCT. However, novel clones appeared and gradually became dominant in a later phase (Figure 3b) . At any point, at least one clone exceeded 20%.
In Case-3, who showed repeated CMV reactivation, some of the donor-dominant CMV-CTL clones were preserved in the early phase, but the novel clone I-24 with CASSSTGGGGAEAFF was the most dominant in the early phase (Figure 3c) . However, the clones became more diverse during the follow-up, and eventually none of the clones exceeded 20% in the later phase.
The maturation analysis was also performed using samples of the later phase. CD27 À CD57 þ mature T cells accounted for 80% of the CMV-pp65 CTLs in Case-1, in whom donor-dominant clones remained dominant. On the other hand, the amount of CD27 þ immature T cells was increased in Cases-2 and -3, both of whom showed novel clones (Figure 4 ).
Difference in HLA-A*2402-restricted CMV-pp65 CTL clones between cultured and non-cultured cells in respective donors CMV-pp65 CTL clones were compared between cultured and noncultured cells of the donors. In Case-1, the dominant clones in cultured cells were detected in non-cultured cells and the proportions of dominant clones were similar (Figure 3a) . However, in both Cases-2 and -3, the proportions of dominant CMV-pp65 CTLs were different between cultured and non-cultured cells, especially in Case-3 (Figures 3b and c) .
Cytotoxicity Two clones were established from Case-1: the most dominant clone N-1 with CASSDPGDSLNGYTF of CDR3, and clone N-X with CASSLSGVDYNEQFF, which was not detected by single-cell analysis at any point. Both clone N-1 and clone N-X showed specific cytotoxicity against CMV-pp65 in a dose-dependent manner. The dominant clone N-1 exhibited 53 and 70% of cytotoxicity at the E:T ratio of 1.25 and 5, respectively. On the other hand, the minor clone N-X exhibited 20 and 30% of cytotoxicity at the corresponding E:T ratios (Figures 5a and b) .
DISCUSSION
Using a direct single-cell analysis of the TCR-b repertoire, we conducted clone monitoring of CMV-pp65 CTLs in three donorrecipient pairs of Allo-HCT and analyzed about 1000 cells. The methods enabled the simultaneous identification and quantification of CTL clones and we could visualize the in vivo dynamics of CMV-pp65 CTL clones without in vitro expansion, which may affect the proportions of CTL clones.
To date, various studies have investigated CMV-specific CTLs [6] [7] [8] [9] [10] 16, 21, 22 and reconstitution after Allo-HCT. 5, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] However, neither flow cytometry using a panel of mAbs to the TCR-BV family 7, 9, 27 nor TCR-BV spectratyping 7, 10 could reflect the dynamics of CMV-CTLs at a clone level. Furthermore, in vitro culture and bacterial transformation are required in a clonotypespecific PCR method, which has been used to identify and quantify CMV-CTL clones. 7, 8, 30 Therefore, it might result in a biased selection of CTL clones according to their proliferative potential. 33, 34 In fact, we observed differences in dominant clones between cultured and non-cultured donor cells in Cases-2 and -3. The current direct single-cell analysis method is important for evaluating the in vivo dynamics of CMV-CTL more precisely.
To the best of our knowledge, this study is the first to describe the comprehensive dynamics and monitoring of CMV-pp65 CTL clones after Allo-HCT. We investigated the clone dynamics in three distinct patterns of CMV reactivation: (1) no CMV reactivation, (2) CMV reactivation only within the early phase and (3) repeated CMV reactivation. Like the results in previous studies, 30, 35 several CMV-pp65 CTL clones in the donors were actually detected in the recipients after Allo-HCT. Especially in Case-1 without CMV reactivation, dominant clones of Donor-1 persisted and remained dominant even after Allo-HCT, which might reflect a high proportion of CD27-CD57 þ mature CMV-pp65 CTLs in Case-1 at 1 year after Allo-HCT. On the other hand, not all of the clones detected in the recipients after Allo-HCT were present in their corresponding donors. Furthermore, we found that dominant clones in a donor were not always dominant in a recipient after Allo-HCT. In Cases-2 and -3 with CMV reactivation, novel clones appeared and became dominant during the follow-up. The emergence of novel clones might be associated with more CD27 þ immature CMV-pp65 CTLs at 1 year after Allo-HCT, especially in Case-3. Single-cell TCR-b analysis of CMV-CTLs in Allo-HCT H Nakasone et al
The cellular response to CMV is known to be frequently impaired and CMV reactivation often occurs in recipients of solid organ transplant or Allo-HCT, even in the presence of CMV-CTL. 21, 26 However, in Case-1, CMV reactivation did not occur despite the long-term use of systemic steroid. One possible explanation for this finding may be the protective phenotype of CMV-CTLs in this patient, compared with those in the other two patients. In Case-1, CMV-pp65 CTLs included about 70% of highly differentiated CD45RA þ CCR7 À T EF cells during follow-up, whereas this value was o30% in the other two patients. Cytokine production and cytotoxicity are known to increase in association with differentiation, and CD45RA þ CCR7 À T EF cells are believed to have high killing potential. 14, 15 The clinical course of CMV reactivation might be affected by the phenotype of CMV-CTLs in the recipients after HCT.
It remains a matter of debate which is important for eliminating infectious pathogens, TCR diversity or selected clones with high avidity. 36 In the previous report, TCR diversity was linked to host resistance against viral infection. 37 On the other hand, another report suggested that TCR diversity had no functional advantage on CTL response. 38 In the current study, Case-1 with highly selected clones seemed to have more advantages on CMV reactivation than Case-3 with more diverse repertoire, although this study is too small to draw a conclusion. Further investigation is necessary to address this issue in allo-HCT recipients.
In previous reports on healthy subjects with HLA-A2 or HLA-B7, dominant clones selected specific BV and BJ genes, and had a particular common AA motif of TCR-b CDR3 in unrelated subjects. 9 In the current study, HLA-A*2402-restricted CMV-pp65 CTLs tended to select BV7 and BJ1-1. Although no common AA motif was found among the cases, GGGG was present in dominant clones in two cases. A larger study will be required to show whether a common motif exists in allo-HCT recipients. Effective immune reconstitution is critical to control CMV reactivation before it progresses to CMV diseases such as pneumonia or colitis, which have high mortality rates. [1] [2] [3] [4] Gauging the TCR repertoire and identifying most effective clonotypes of CMV-CTLs may lead to a specific immunotherapy against treatment-refractory CMV infection, as in anticancer therapy. 39 This study had several limitations and challenges regarding the methodology. First, our study included only three donor-patient pairs, although the clonotypes of about 1000 cells were analyzed. Therefore, we could not form any definite conclusions regarding the association between clinical CMV reactivation and the dynamics of CMV-pp65 CTL clones. 26, [28] [29] [30] Second, it should be noted that the proportion of HLA-A*2402-restricted CMV-CTLs was quite low at later time points, especially in Case-3. Phenotypic analysis might be susceptible to the low number. Third, clones of CMV-pp65 CTLs in Cases-2 and -3 could not be established by the current experimental methods. This may have been due to the exposure to steroid or GVHD. To compare the cytotoxicities and cytokine production of CMV-pp65 CTL clones, a method that enables sufficient cell proliferation from a single cell will need to be established.
In summary, we focused on the reconstitution of HLA-A*2402-restricted CMV-pp65 CTLs following allo-HCT, and performed clone monitoring using a single-cell analysis method. HLA-A*2402-restricted CMV-pp65 CTLs tended to select BV7 and BJ1-1. The phenotypes and in vivo dynamics of CMV-pp65 CTLs differed according to three distinct patterns of CMV reactivation. A larger study is warranted to assess the association between CMV reactivation and reconstitution patterns of CMV-CTLs. In vivo clone monitoring of CMV-CTLs could provide insight into the mechanism of immunological reconstitution following allo-HCT.
